Tongjitang Chinese Medicines Company had the unfortunate responsibility of informing investors that, once again, its revenues for the quarter were lower than the year-earlier period. Trying to put a good face on the news, Tongjitang led its announcement by saying that Q2 revenues were up 13% from Q1, a hopeful sign. Still, the unavoidable fact remains that its Q2 sales, which came in at $17.4 million, were down 15% from 2007’s second quarter. The company’s problem remains that competitors are selling counterfeit versions of its flagship product, the TCM osteoporosis treatment Xianling Gubao. More details...

Stock Symbol: (NYSE: TCM)